MedTrace Logo

Onsite Buprenorphine Treatment at Syringe Exchange Programs

NCT03150173 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 97

Last updated 2025-12-11

Study results available
· View outcomes & findings →

Summary

This trial will recruit syringe exchange participants with opioid use disorder in New York City and test whether starting buprenorphine treatment at the syringe exchange program is more effective than referral to a community health center for buprenorphine treatment.

Conditions

  • Opiate Addiction

Interventions

BEHAVIORAL

Onsite treatment

Participants will see a buprenorphine treatment provider who will assess for clinical criteria for opioid use disorder and write a prescription for buprenorphine treatment, which will be filled in a community pharmacy.

BEHAVIORAL

Enhanced referral

Participants will receive an expedited appointment at a community health center for evaluation for buprenorphine treatment

DRUG

Buprenorphine

all participants will receive buprenorphine

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • Montefiore Medical Center

    lead OTHER

Principal Investigators

  • Aaron Fox, MD, MS · Associate Professor of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-02
Primary Completion
2023-10-11
Completion
2024-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03150173 on ClinicalTrials.gov